These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31600834)

  • 1. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Liu F; Goh GB; Tiniakos D; Wee A; Leow WQ; Zhao JM; Rao HY; Wang XX; Wang Q; Wan WK; Lim KH; Romero-Gomez M; Petta S; Bugianesi E; Tan CK; Harrison SA; Anstee QM; Chang PJ; Wei L
    Hepatology; 2020 Jun; 71(6):1953-1966. PubMed ID: 31600834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing a New qFIBS Model Assessing Histological Features in Pediatric Patients With Non-alcoholic Steatohepatitis.
    Liu F; Wei L; Leow WQ; Liu SH; Ren YY; Wang XX; Li XH; Rao HY; Huang R; Wu N; Wee A; Zhao JM
    Front Med (Lausanne); 2022; 9():925357. PubMed ID: 35833109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
    Naoumov NV; Brees D; Loeffler J; Chng E; Ren Y; Lopez P; Tai D; Lamle S; Sanyal AJ
    J Hepatol; 2022 Nov; 77(5):1399-1409. PubMed ID: 35779659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
    J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.
    Pavlides M; Banerjee R; Tunnicliffe EM; Kelly C; Collier J; Wang LM; Fleming KA; Cobbold JF; Robson MD; Neubauer S; Barnes E
    Liver Int; 2017 Jul; 37(7):1065-1073. PubMed ID: 27778429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.
    Leung HH; Puspanathan P; Chan AW; Nik Mustapha NR; Wong VW; Chan WK
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1131-1138. PubMed ID: 35362158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective.
    Soon G; Wee A
    Clin Mol Hepatol; 2021 Jan; 27(1):44-57. PubMed ID: 33207115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second Harmonic Generation Reveals Subtle Fibrosis Differences in Adult and Pediatric Nonalcoholic Fatty Liver Disease.
    Liu F; Zhao JM; Rao HY; Yu WM; Zhang W; Theise ND; Wee A; Wei L
    Am J Clin Pathol; 2017 Nov; 148(6):502-512. PubMed ID: 29165568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH).
    Giashuddin S; Alawad M
    Methods Mol Biol; 2022; 2455():1-18. PubMed ID: 35212981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    Brunt EM; Clouston AD; Goodman Z; Guy C; Kleiner DE; Lackner C; Tiniakos DG; Wee A; Yeh M; Leow WQ; Chng E; Ren Y; Boon Bee GG; Powell EE; Rinella M; Sanyal AJ; Neuschwander-Tetri B; Younossi Z; Charlton M; Ratziu V; Harrison SA; Tai D; Anstee QM
    J Hepatol; 2022 May; 76(5):1030-1041. PubMed ID: 35090960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen co-localized with macrovesicular steatosis better differentiates fibrosis progression in non-alcoholic fatty liver disease mouse models.
    Wang XX; Jin R; Li XH; Yang Q; Teng X; Liu FF; Wu N; Rao HY; Liu F
    Front Med (Lausanne); 2023; 10():1172058. PubMed ID: 37332758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
    Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
    J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH.
    De Rudder M; Bouzin C; Nachit M; Louvegny H; Vande Velde G; Julé Y; Leclercq IA
    Lab Invest; 2020 Jan; 100(1):147-160. PubMed ID: 31506634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver biopsy in the quantitative assessment of liver fibrosis in nonalcoholic fatty liver disease.
    Ting Soon GS; Wee A
    Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S104-S111. PubMed ID: 34135151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.